 Vaughn Browne
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Altitude | 12 | 2020 | 422 | 1.440 |
Why?
| | Uterine Artery | 6 | 2020 | 65 | 1.070 |
Why?
| | Cardiac Tamponade | 1 | 2022 | 16 | 0.880 |
Why?
| | Fetal Growth Retardation | 5 | 2013 | 468 | 0.560 |
Why?
| | Regional Blood Flow | 3 | 2015 | 418 | 0.560 |
Why?
| | Fetal Hypoxia | 2 | 2015 | 46 | 0.510 |
Why?
| | Pre-Eclampsia | 2 | 2020 | 183 | 0.480 |
Why?
| | Fetal Development | 2 | 2015 | 250 | 0.440 |
Why?
| | Fetus | 2 | 2015 | 690 | 0.410 |
Why?
| | Papillary Muscles | 4 | 2004 | 13 | 0.410 |
Why?
| | Vascular Resistance | 2 | 2020 | 356 | 0.390 |
Why?
| | Biological Evolution | 1 | 2015 | 443 | 0.390 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2011 | 46 | 0.380 |
Why?
| | Hypoxia | 6 | 2017 | 963 | 0.350 |
Why?
| | Myocardial Contraction | 3 | 1997 | 339 | 0.300 |
Why?
| | Pregnancy Complications | 3 | 2017 | 448 | 0.300 |
Why?
| | Pregnancy | 13 | 2020 | 5694 | 0.270 |
Why?
| | Point-of-Care Systems | 2 | 2017 | 151 | 0.260 |
Why?
| | Ultrasonography | 4 | 2017 | 716 | 0.260 |
Why?
| | Fetal Heart | 3 | 2004 | 29 | 0.250 |
Why?
| | Bolivia | 6 | 2017 | 60 | 0.240 |
Why?
| | Acclimatization | 2 | 2013 | 135 | 0.190 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.180 |
Why?
| | Birth Weight | 2 | 2014 | 465 | 0.170 |
Why?
| | Uterus | 1 | 2020 | 197 | 0.160 |
Why?
| | Altitude Sickness | 2 | 2013 | 163 | 0.160 |
Why?
| | Gestational Age | 5 | 2014 | 765 | 0.160 |
Why?
| | Paracentesis | 1 | 2017 | 7 | 0.150 |
Why?
| | Education, Premedical | 1 | 2016 | 4 | 0.150 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1997 | 144 | 0.150 |
Why?
| | Receptors, Erythropoietin | 1 | 2017 | 25 | 0.150 |
Why?
| | Heart | 2 | 1997 | 631 | 0.150 |
Why?
| | Ultrasonics | 1 | 2016 | 53 | 0.140 |
Why?
| | Abscess | 1 | 2017 | 75 | 0.140 |
Why?
| | Computer-Assisted Instruction | 1 | 2017 | 66 | 0.140 |
Why?
| | Phantoms, Imaging | 1 | 2017 | 139 | 0.140 |
Why?
| | Erythropoietin | 1 | 2017 | 82 | 0.140 |
Why?
| | Ultrasonography, Doppler | 2 | 2020 | 104 | 0.140 |
Why?
| | Pulse | 1 | 2015 | 27 | 0.140 |
Why?
| | Simulation Training | 1 | 2017 | 66 | 0.140 |
Why?
| | Palpation | 1 | 2015 | 19 | 0.130 |
Why?
| | Calcium | 2 | 2004 | 1171 | 0.130 |
Why?
| | Adaptation, Physiological | 2 | 2017 | 502 | 0.130 |
Why?
| | Receptor, Endothelin A | 1 | 2014 | 60 | 0.120 |
Why?
| | Femoral Artery | 1 | 2015 | 175 | 0.120 |
Why?
| | Vascular Diseases | 1 | 2017 | 241 | 0.120 |
Why?
| | Placenta | 1 | 2020 | 641 | 0.120 |
Why?
| | Teaching | 1 | 2015 | 236 | 0.110 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 179 | 0.110 |
Why?
| | Optic Nerve | 1 | 2013 | 65 | 0.110 |
Why?
| | Blood Flow Velocity | 2 | 2011 | 327 | 0.110 |
Why?
| | Education, Medical, Undergraduate | 1 | 2015 | 199 | 0.110 |
Why?
| | Students, Medical | 1 | 2017 | 311 | 0.110 |
Why?
| | PPAR gamma | 1 | 2013 | 189 | 0.110 |
Why?
| | Students | 1 | 2016 | 509 | 0.100 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2013 | 124 | 0.100 |
Why?
| | Enzymes | 1 | 2011 | 66 | 0.100 |
Why?
| | Infant, Small for Gestational Age | 1 | 2011 | 73 | 0.100 |
Why?
| | Female | 16 | 2020 | 61588 | 0.100 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2011 | 33 | 0.100 |
Why?
| | Heart Rate | 1 | 2015 | 729 | 0.100 |
Why?
| | Live Birth | 1 | 2011 | 47 | 0.100 |
Why?
| | Iliac Artery | 1 | 2011 | 44 | 0.100 |
Why?
| | Case-Control Studies | 3 | 2017 | 3173 | 0.100 |
Why?
| | Young Adult | 7 | 2020 | 10799 | 0.100 |
Why?
| | Angiostatic Proteins | 1 | 2010 | 5 | 0.100 |
Why?
| | Stillbirth | 1 | 2011 | 58 | 0.100 |
Why?
| | Homeostasis | 1 | 2014 | 594 | 0.090 |
Why?
| | Angiogenic Proteins | 1 | 2010 | 21 | 0.090 |
Why?
| | Curriculum | 1 | 2016 | 910 | 0.090 |
Why?
| | Humans | 16 | 2022 | 119032 | 0.090 |
Why?
| | Ultrasonography, Prenatal | 1 | 2011 | 227 | 0.090 |
Why?
| | Adult | 11 | 2020 | 31525 | 0.090 |
Why?
| | Sheep | 4 | 2004 | 764 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2014 | 2062 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2010 | 379 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2017 | 4552 | 0.080 |
Why?
| | Antioxidants | 1 | 2011 | 564 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2011 | 1295 | 0.080 |
Why?
| | Models, Biological | 1 | 2015 | 1715 | 0.080 |
Why?
| | Premature Birth | 1 | 2011 | 284 | 0.080 |
Why?
| | Ginkgo biloba | 1 | 2005 | 6 | 0.070 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2005 | 18 | 0.070 |
Why?
| | Acetazolamide | 1 | 2005 | 28 | 0.060 |
Why?
| | Plant Preparations | 1 | 2005 | 23 | 0.060 |
Why?
| | Middle Aged | 3 | 2022 | 27627 | 0.060 |
Why?
| | Phytotherapy | 1 | 2005 | 69 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2446 | 0.060 |
Why?
| | Troponin I | 1 | 2004 | 83 | 0.060 |
Why?
| | Cytokines | 1 | 2010 | 1900 | 0.050 |
Why?
| | Indians, South American | 2 | 2013 | 23 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2017 | 1795 | 0.050 |
Why?
| | Electric Stimulation | 2 | 2004 | 268 | 0.050 |
Why?
| | Cohort Studies | 3 | 2020 | 5117 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2017 | 2874 | 0.040 |
Why?
| | Colforsin | 1 | 1997 | 55 | 0.040 |
Why?
| | Isoproterenol | 1 | 1997 | 125 | 0.040 |
Why?
| | Isradipine | 1 | 1997 | 4 | 0.040 |
Why?
| | Ryanodine | 1 | 1997 | 13 | 0.040 |
Why?
| | Heart Ventricles | 2 | 2004 | 727 | 0.040 |
Why?
| | Adrenergic beta-Agonists | 1 | 1997 | 132 | 0.040 |
Why?
| | Cyclic AMP | 1 | 1997 | 242 | 0.040 |
Why?
| | Organ Size | 1 | 1997 | 460 | 0.040 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 1997 | 59 | 0.040 |
Why?
| | Equipment Failure Analysis | 1 | 2017 | 139 | 0.040 |
Why?
| | Reference Values | 1 | 1997 | 775 | 0.030 |
Why?
| | Calcium Channels | 1 | 1997 | 150 | 0.030 |
Why?
| | Calcium Channels, L-Type | 1 | 1997 | 110 | 0.030 |
Why?
| | California | 1 | 2017 | 382 | 0.030 |
Why?
| | Muscle Proteins | 1 | 1997 | 219 | 0.030 |
Why?
| | Equipment Design | 1 | 2017 | 519 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1997 | 1096 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 1997 | 257 | 0.030 |
Why?
| | Mentoring | 1 | 2016 | 101 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 1997 | 586 | 0.030 |
Why?
| | Receptor, Endothelin B | 1 | 2014 | 53 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 827 | 0.030 |
Why?
| | Receptors, Endothelin | 1 | 2014 | 49 | 0.030 |
Why?
| | Universities | 1 | 2016 | 347 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 1997 | 468 | 0.030 |
Why?
| | Radiology | 1 | 2017 | 199 | 0.030 |
Why?
| | Tibet | 1 | 2013 | 28 | 0.030 |
Why?
| | South America | 1 | 2013 | 56 | 0.030 |
Why?
| | Gene Frequency | 1 | 2014 | 513 | 0.030 |
Why?
| | Intracranial Pressure | 1 | 2013 | 53 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 239 | 0.030 |
Why?
| | Intracranial Hypertension | 1 | 2013 | 41 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2014 | 371 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2013 | 5256 | 0.030 |
Why?
| | Linear Models | 1 | 2014 | 827 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 369 | 0.030 |
Why?
| | Geography | 1 | 2011 | 190 | 0.020 |
Why?
| | Selection, Genetic | 1 | 2013 | 252 | 0.020 |
Why?
| | Hemoglobins | 1 | 2013 | 326 | 0.020 |
Why?
| | Placenta Growth Factor | 1 | 2010 | 25 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2010 | 38 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 67 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2424 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 941 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2513 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 216 | 0.020 |
Why?
| | Animals | 4 | 2004 | 33399 | 0.020 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 256 | 0.020 |
Why?
| | Pedigree | 1 | 2010 | 485 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 525 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1882 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 3443 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2010 | 306 | 0.020 |
Why?
| | Clinical Competence | 1 | 2015 | 951 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 872 | 0.020 |
Why?
| | Male | 4 | 2017 | 57818 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1323 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4596 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1637 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 692 | 0.020 |
Why?
| | Health Status | 1 | 2011 | 726 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3590 | 0.020 |
Why?
| | Colorado | 1 | 2015 | 4196 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1175 | 0.020 |
Why?
| | Egtazic Acid | 1 | 2004 | 44 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2005 | 403 | 0.010 |
Why?
| | Cardiac Output | 1 | 2004 | 147 | 0.010 |
Why?
| | Actin Cytoskeleton | 1 | 2004 | 100 | 0.010 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 140 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2275 | 0.010 |
Why?
| | Infant | 1 | 2014 | 8295 | 0.010 |
Why?
| | Risk Assessment | 1 | 2010 | 3057 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2005 | 1687 | 0.010 |
Why?
| | Phosphorylation | 1 | 2004 | 1634 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 9346 | 0.010 |
Why?
| | Prospective Studies | 1 | 2010 | 6477 | 0.010 |
Why?
| | Risk Factors | 1 | 2010 | 9003 | 0.010 |
Why?
| | Aged | 1 | 2013 | 19661 | 0.010 |
Why?
| | Adolescent | 1 | 2013 | 18483 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1997 | 1947 | 0.010 |
Why?
| | Oxygen | 1 | 1997 | 857 | 0.010 |
Why?
|
|
Browne's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|